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Background: Cancer stem cells (CSCs) are notorious for their capacity of tumor progression, metastasis or
resistance to chemo-radiotherapy. However, the undisputed role of cancer stem marker, CD133, in colorectal
cancers (CRCs) is not clear yet.
Methods: We assessed 271 surgically-resected stage II and III primary CRCs with (171) and without (100) adjuvant
therapy after surgery. CD133 expression was analyzed by immunohistochemical (IHC) staining and real-time RT-PCR.
CD133 promoter methylation was quantified by pyrosequencing.
Results: The CD133 IHC expression was significantly correlated with mRNA expression (p=0.0257) and inversely
correlated with the promoter methylation (p=0.0001). CD133 was expressed more frequently in rectal cancer
(p=0.0035), and in moderately differentiated tumors (p=0.0378). In survival analysis, CD133 expression was not
significantly correlated with overall survival (OS) (p=0.9689) as well as disease-free survival (DFS) (p=0.2103).
However, CD133+ tumors were significantly associated with better OS in patients with adjuvant therapy
compared to those without adjuvant therapy (p<0.0001, HR 0.125, 95% CI 0.052-0.299). But the patients with
CD133- tumors did not show any significant difference of survival according to adjuvant therapy (p=0.055, HR
0.500, 95% CI 0.247-1.015).
Conclusions: In stage II and III CRCs, CD133 IHC expression may signify the benefit for adjuvant therapy
although it is not an independent prognostic factor.
Keywords: Cancer stem cell, CD133 protein, Human, Colorectal neoplasms, Immunohistochemistry,
Chemoradiotherapy, Adjuvant, PrognosisBackground
Cancer stem cells (CSC)s are undifferentiated cells that
expand their colony through asymmetric cell division, the
result of which is two daughter cell population, one being
similar to the mother cells, retaining stem cell properties,
while the other one is committed to undergo a specified
differentiation [1]. CSCs have been isolated from many* Correspondence: meeyon@yonsei.ac.kr
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(CRC)s and they have been defined to have the capacity of
self-renewal and multipotency [2] and ability to maintain
the stem cell pool and most elements of the tumor for
unlimited time period [3,4] being responsible for tumor
initiation and progression [5], resistance against chemo-
radiotherapy, and relapse after initial eradication [6].
Different markers have been found to be expressed on
the surface of CSCs, out of which CD133 has retained
much attention and importance. The CD133+ population
exists among cancer initiating cells in many tissues, includ-
ing colon [7], breast [8], lung [9], stomach [10], liver [11],l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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carcinomas [15], leukemia [16], glioma [17], and medullo-
blastoma [18].
CD133 or Prominin-1 is a pentaspan transmembrane
glycoprotein [19], whose gene is located on chromosome
4p15.32. CD133 comprises five transmembrane domains
and two large glycosylated extracellular loops [20]. Three
of the five promoters responsible for CD133 transcrip-
tion are located in a CpG island [21]. Thus, epigenetic
factors can complicate the regulation of CD133 gene
transcription [22]. DNA hypomethylation is accounted
as an important determinant of CD133 expression [23];
however, yet the regulatory mechanism of CD133 gene
transcription is not utterly understood.
CD133 expression is reported to be indicative of a re-
sistance phenotype [24], poor prognosis [25], and are be-
lieved to mediate cancer relapse after chemotherapy [26]
and lower level of CD133 mRNA expression are docu-
mented to be associated with a longer relapse-free inter-
val and overall survival (OS) in colon cancer [27].
Controversially, it was recently shown that CD133+ cells
are not more resistant to chemotherapy than CD133−
cells [28]. On the other hand, the evidence provided by
Huang, E. H. et al., shows that nude mice injected with
CD133 negative colon cancer cells developed cancer
[29]. Moreover, Du. L. et al. have demonstrated that
knock-down of CD133 does not compromise the tumor-
initiating capabilities of colon cancer cells, questioning a
functional role of this molecule for the colon cancer
stem cells [30].
In this study, we evaluated CD133 expression by im-
munohistochemical (IHC) stains and real-time RT-PCR
in CRCs. In addition, promoter methylation status was
analyzed by pyrosequencing. We further analyzed the
prognostic significance of CD133 expression in CRCs
and correlation of promoter methylation status with
IHC and mRNA expression.
Methods
Patients and tissue samples
This retrospective study included the patients who had
surgically resected stage II and III CRC and available
follow-up information from January 2000 to December
2006. For the comparison, we divided the patients
according to the tumor location and either receiving
adjuvant treatment or no adjuvant treatment. The pa-
tients receiving preoperative chemotherapy or radio-
therapy were excluded. Clinicopathologic data for
parameters such as patient’s age, gender, tumor loca-
tion, invasion depth, histologic differentiation, and
lymph node metastasis were collected from the path-
ology report. For the comparison, we also performed
CD133 IHC staining on non-neoplastic gastric mucosa
and pancreatic parenchyma.Ethics approval
The study has been approved by the Institutional Ethic
Committee of Yonsei University, Wonju College of
Medicine (YWMR-12-4-031) and has been carried out
in compliance with the guidelines of the Declaration of
Helsinki.
Adjuvant chemotherapy and follow-up
Patients were planned to receive 5th cycles to 12 cycles
of adjuvant FOLFOX chemotherapy within a six-month
period. The patients received a 2-hour infusion of 85 mg
of oxaliplatin per square meter on day 1, in addition to
the standard LV5FU2 regimen (FOLFOX4) or the sim-
plified LV5FU2 regimen (modified FOLFOX6). After
surgery, tumor recurrence was detected by physical
examination, serum CEA antigen assay, and abdominal
imaging every three to six months for 3 years, every six
months for the following 2 years, and then annually. The
duration of follow-up was defined as the time between
surgery and disease recurrence (DFS), death (OS), or last
hospital contact (scheduled follow-up or telephone con-
tact). Maximum follow-up period was 108.3 months.
Immunohistochemical analysis
Paraffin-embedded tissue sections from well represen-
tative blocks were deparaffinized with xylene and then
rehydrated through graded alcohol solutions. Antigen
retrieval (according to manufacturer’s instructions)
consisted of slide warm-up to 75°C and incubation (4 min),
applying cell conditioning solution #2 (60 min) (Ventana
medical system, Roche, Tucson, USA). Endogenous perox-
idase was blocked by applying UV inhibitor (4 min). The
slides were washed with reaction buffer. The UltraView
Universal DAB Detection Kit was used for IHC stain-
ing. The steps are briefly described as following. The
primary antibody (CD133/1 (AC133) pure, Human,
MACS, Miltenyi Biotec, CA, USA) was applied and in-
cubated for 2 hrs at a 1:100 dilution in Ventana ma-
chine (BenchmarkXT, Ventana medical system, Roche,
Tucson, USA). Slides were then rinsed with reaction
buffer and added one drop of HRP UNIV MULT, DAB
and DAB H2O2 (Ventana medical system, Roche,
Tucson, USA) (8 min each), consecutively with inter-
mittent rinsing with reaction buffer. Slides were then
treated with one drop of COPPER (4 min) before
counterstaining with hematoxylin (4 min), followed by
bluing agent and finally rinsed with reaction buffer.
The IHC staining was scored as 0 when there was no
expression at all, 1+ when the expression of CD133 was
detected in 1-10% of the whole tumor area, 2+ and 3+
when it was expressed in 11-50% and 51-100% of the
tumor area, respectively. Tumors with CD133 expression
on over 10% of whole tumor area were considered as
CD133 positive.
Table 1 The number of patients according to adjuvant
therapy in colon and rectum*
Location Adjuvant therapy
(stage II + stage III)
No adjuvant therapy
(stage II + stage III)
Total (stage
II + stage III)
Colon 91 (40 + 51) 59 (38 + 21) 150 (78 +72)
Rectum 80 (23 + 57) 41 (21 + 20) 121 (44 + 77)
Total 171 (63 + 108) 100 (59 + 41) 271 (122 + 149)
*p=0.3337.
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by two pathologists blinded to the patients’ clinical and
pathologic information. Discrepancies between the pa-
thologists were resolved by consensus.
RNA Extraction and cDNA synthesis
Fresh frozen tissues after surgery were available for 75
out of 271 cases.
The total RNA was extracted from 20 mg colorectal
frozen tissue, using RNeasy plus Mini kit (QIAGEN
Hilden, Germany) according to manufacturer’s protocol
and Quantitect Reverse Transcription kit (QIAGEN
Hilden, Germany) was used for cDNA synthesis from
500ng of total RNA.
Quantitative RT-PCR
Real-time RT-PCR was performed [as described else-
where [31] in 384 well PCR plates containing the Fast
SYBR Green Master Mix (Applied Biosystems, California,
USA), cDNA template, CD133 RT sense primer (5'-
CTGGGGCTGCTGT TTATTATTCTG-3'), and CD133
RT antisense primer (5'-ACGCCTTGTCCTTGGTAGT
GTTG-3') in a final volume of 10 μL. Each primer/
cDNA set was set up in triplicate. Real-time PCR reac-
tions in a 7900HT Fast Real-Time PCR System (Applied
Biosystems) were initiated by heating to 50°C for 2 min
and then to 95°C for 10 min, followed by 40 cycles of
95°C (15 s), and 60°C (60 s). The relative quantification
of gene expression was performed using the ΔΔCt
method.
Bisulfite conversion and pyrosequencing analysis of DNA
methylation
We extracted DNA from microdissected sample using
DNeasy Blood and Tissue kit (QIAGEN, Hilden, Germany)
according to manufacturer’s instructions. Genomic DNA
was modified with sodium bisulfite using an EpiTectW Bi-
sulfite kit (QIAGEN Hilden, Germany) according to manu-
facturer’s instruction. Methylation status of CD133 was
assessed using pyrosequencing-based methylation analysis.
We evaluated the methylation status of CpG sites in pro-
moter P2 and exon 1B, as these sites have previously
shown correlation with CD133 gene transcript [31].
All primers for pyrosequencing were designed with
Pyrosequencing Assay Design (QIAGEN, Hilden, Germany).
Bisulfite-treated genomic DNA was used as a template in
subsequent polymerase chain reactions. For each gene, a
30 ul PCR was carried out with HotStarTaqPlus Master Mix
(QIAGENE, Hilden, Germany) to label bisulfite converted
DNA with biotinylated primers (CD133 promoter site: For-
ward 5’-GGAGTAGGGATATGGGGGTATAAA-3’, Reverse
primer 5’- AAACACCCCAATTCTCCATCT-3’). The PCR
conditions included denaturation 94°C (30 s), annealing
54°C (30 s), extension 72°C (30 s) and 40 cycle. After PCR,the biotinylated strand was captured on streptavidin-coated
beads (Amersham Bioscience, Uppsala, Sweden) and incu-
bated with sequencing primers (5’- GGGATATGGGGGT
ATAAA-3’). The sequencing primer includes four methyla-
tion sites (GYGAGGTTATTTTTTYGYGTTYGTGGG).
Pyrosequencing was performed with PSQ HS 24 Gold
single-nucleotide polymorphism reagents on a PSQ HS 24
pyrosequencing machine (Biotage, Uppsala, Sweden).
Statistical analysis
χ 2-test and Mantel-Haenszel test were used to analyze
the categorical data. We used Pearson correlation to
compare distributions of qualitative variables. Survival
curve was estimated with the Kaplan-Meier method and
compared using the log-rank test. Multivariate Cox pro-
portional hazard regression model was used to estimate
the hazard ratio (HR) and 95% confidence interval (CI)
with adjustment for age and stage. Analyses were
performed using SAS (Version 9.2, SAS Inc., North




In this study, 161 male and 110 female patients were in-
cluded in a randomized manner. Mean age for all 271
patients was 63.166 years (range 27–101). The character-
istics of patients analyzed in this study according to
tumor location and adjuvant therapy status is summa-
rized in Tables 1 & 2.
CD133 Immunohistochemical expression according to the
clinicopathologic variables
A weak CD133 IHC expression in non-neoplastic colo-
rectal mucosa around the tumor was noted in a few
scattered cells (Figure 1A) and luminal border at the
base of normal crypts (Figure 1B). On the contrary, we
observed weak but frequent CD133 expression in non-
neoplastic pyloric gland of stomach in some cases but
not in fundic glands or mucus neck cells (Figure 1C). In
pancreas, there are diffuse and strong CD133 expression
in luminal border of non-neoplastic pancreatic duct as
well as acini in all cases examined (Figure 1D).
In colorectal carcinoma, CD133 IHC expression was
seen exclusively on the cell membrane at the glandular
Table 2 The number of patients according differentiation
in colon and rectum*
Location Well (%) Moderate (%) Poor (%) Total (%)
Colon 9 (6.00) 121 (80.66) 20 (13.33) 150 (100)
Rectum 7 (5.78) 104 (85.95) 10 (8.26) 121 (100)
Total 16 (5.90) 225 (83.02) 30 (11.07) 271 (100)
*p=0.4065.
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(Figure 2A-D & 2F). Few tumors with poor differenti-
ation (Figure 2C), tumor budding and mucinous adeno-
carcinomas (Figure 2D) showed focal CD133 expression
in areas with abortive glands or intracytoplasmic luminal
structure. Some tumors with poor histologic grade and
mucinous adenocarcinomas showed dot-like cytoplasmic
staining (Figure 2E). The intraglandular debris of shed
tumor cells in some cases showed CD133 immunoreactivity,
which were not taken into account. CD133 expression
according to the clinicopathologic parameters are demon-
strated in Table 3. In χ2- analysis and Mantel-Haenszel test,
CD133 IHC expression was significantly different according
to histologic differentiation (p=0.0378) and tumor location
(colon vs. rectum) (p=0.0158, Table 3). The moderately dif-
ferentiated tumors and rectal tumors showed more CD133Figure 1 Photomicrographs of CD 133 IHC expression in non-neoplas
of stomach and pancreas. (A) CD133 positive cells are very rarely found i
(X 400 hematoxylin counterstained). In contrast to the colon, (C) the non-n
distinct and diffuse staining in the luminal border. (X 200 hematoxylin counexpression than others. There was no significant relationship
between CD133 IHC expression and other clinicopathologic
variables studied such as sex (p=0.8233), pTNM stage
(p=0.3598), invasion depth (p=0.160), and lymph node me-
tastasis (p=0.346).CD133 mRNA expression
Available fresh frozen tumor tissues from 75 cancers (21
colon and 54 rectum) among 271 CRCs were used for
real-time RT-PCR to measure CD133 mRNA expression.
The mRNA expression was found to be significantly cor-
related with the CD133 IHC expression (Table 4)
(p=0.0257).The correlation between CD133 expression and promoter
methylation
CD133 promoters were more hypomethylated (Table 4)
in cases with higher CD133 IHC expression, while
hypermethylation was noted in cases with lower CD133
IHC expression. This inverse correlation between CD133
IHC expression and promoter methylation was statistically
significant (p=0.0001). However, CD133 mRNA expres-
sion level was not significantly correlated with promoter
methylation (p=0.1113).tic colonic mucosa in comparison with the non-neoplastic glands
n normal colon crypts and (B) along the luminal border of few crypts.
eoplastic pyloric glands and (D) pancreatic duct or acini show a
terstained).
Figure 2 The CD133 IHC expression according to the histologic differentiation of tumors. CD133 is expressed along the glandular luminal
side in (A) well-differentiated, (B) moderately differentiated, (C) poorly differentiated tumors, and (D) mucinous adenocarcinomas. Dot-like
cytoplasmic staining is observed in poor histologic differentiation (E). CD133 IHC expression is also detected in cancer cells in invasive front (black
arrows) (F). (X 100 hematoxylin counterstained).
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patients according to the adjuvant treatment
In multivariate analysis, CD133 IHC expression was not
an independent prognostic factor in stage II and III colo-
rectal cancer in this study. Patients receiving adjuvant
therapy have a significantly longer OS time compared to
those without adjuvant therapy (p<0.0001). And among
the group with CD133+ tumors in this study (>10%,
n=130), patients with adjuvant therapy (n=85) had a bet-
ter OS compared to those without adjuvant therapy
(n=45) (p<0.0001, HR 0.125, 95% CI 0.052-0.299,
Figure 3). However, the CD133- tumors (≤10%, n=141)
did not show significant difference between two groups
(n=86 vs. 55, p=0.055, HR 0.500, 95% CI 0.247-1.015,
Figure 4). There was no significant correlation betweenCD133 IHC expression and DFS according to adjuvant
therapy (p=0.2451). CD133 mRNA also was not signifi-
cantly correlated with patients’ survival (p=0.3186) or re-
currence of tumors (p=0.3198) in Cox proportional
regression test adjusted with age, stage, and adjuvant
therapy. Due to limited number of cases with available
fresh frozen tissue, we could not analyze the prognostic
significance of mRNA expression according to adjuvant
therapy.
Discussion
The CSC theory finds a concrete basis of rationality in
colorectal cancer owing to the fact that colon epithelium
physiologically regenerates and is shed periodically over a
short span of time not compatible with traditional model











Variables N % % % %
Gender
Male 161 27.95 23.60 22.98 25.46
Female 110 32.72 20.00 20.00 27.27
Tumor site*
Colon 150 37.33 22.66 17.33 17.33
Rectum 121 20.66 21.48 27.27 30.57
pTNM stage
II 122 31.14 25.40 22.13 21.31
III 149 28.85 19.46 21.47 30.20
pT stage
T1 4 75.00 0 0 25.00
T2 6 16.66 66.66 16.66 0
T3 239 29.70 21.75 22.17 26.35
T4 22 27.27 18.18 22.72 31.81
pN stage
N0 123 30.90 25.20 21.95 21.95
N1 88 29.54 17.04 25.00 28.40
N2 56 26.78 25.00 17.85 30.35
N3 4 50.00 0 0 50.00
Histologic differentiation*
Well 16 37.50 31.25 18.57 12.50
Moderate 225 25.33 22.22 22.66 29.77
Poor 15 53.33 20 26.66 0
Mucinous adenocarcinoma 15 66.66 13.33 6.66 13.33
Adjuvant therapy
Yes 171 28.07 22.22 18.71 30.99
No 100 33.00 22.00 27.00 18.00
* p<0.05.
Table 4 Cross-table showing correlation among CD133
IHC staining, mRNA expression and methylation level in




















Mia-Jan et al. BMC Cancer 2013, 13:166 Page 6 of 10
http://www.biomedcentral.com/1471-2407/13/166of carcinogenesis according to which cells ought to be
more long-lived and suffer several mutations and genetic
alterations to be able to convert to a cancer cell [32,33].
We described the distribution and prognostic signifi-
cance of CSC marker, CD133 expression in 271 CRCs in
this study. CD133 was expressed in 47.97% of CRCs. It is
higher than previously reported. Previous studies have re-
vealed controversial findings regarding the pattern (cyto-
plasmic vs. membranous) and distribution of CD133 IHC
staining in CRCs. These differences in previous reports
could arise from using different antibodies, tissue samples
(cell lines vs. human tissue), methods of detection (IHC
expression vs. PCR based techniques) [34], and tissue
sampling method (tissue microarray vs. individually
mounted tissue slides) and method for scoring the
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Figure 3 Kaplan-Meier survival curves in the CD133+ (≥10% expression) colorectal cancer patients according to adjuvant therapy
status. The patients with CD133+ CRC had a significantly shorter OS if they had not received adjuvant therapy (p=0.0001).
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CD133 positivity was quantitatively graded [35], we
used four-tiered scoring method comprising 0 (totally
negative cases), 1+, 2+, and 3+ cases (CD133+ cells
covering 1-10%, 11-50%, and 51-100%, of the tumor area,
respectively). Nevertheless, we considered the 2+ and 3+
groups as CD133 positive.
On the other hand, due to the fact that CD133 is not
homogenously expressed and inability of microarray to
fully represent the whole tumor, we used individually-
mounted whole-block tissue slides for IHC analysis. Fur-
thermore, to decrease the staining bias, we used automated
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STRATA: ADJVNT=No
ADJVNT=Yes
Figure 4 Kaplan-Meier survival curves in the CD133- (<10% expressio
status. There was no statistically significant difference in OS according to tIn line with findings of previous studies on colon
[36-38] tumors with moderately differentiation showed
higher level of CD133 IHC expression compared to
poorly differentiated tumors and mucinous adenocarcin-
omas. No difference was noted in IHC expression be-
tween superficial and deep areas (Figure 2F). We rarely
found unequivocal cytoplasmic or luminal staining at
the crypt base in non-neoplastic colonic mucosa around
the tumor, similar to the results of previous studies
[20,26,39]. In comparison with the CD133 IHC expres-
sion of non-neoplastic colonic mucosa, there are more
frequent and strong CD133 expression in the luminal
border of non-neoplastic mucosa of stomach ande_death
2000 2500 3000 3500
Censored ADJVNT=No
Censored ADJVNT=Yes
n) colorectal cancer patients according to adjuvant therapy
he adjuvant therapy status (p=0.055).
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sults, further study seems to be required to clarify
whether CD133 is a colon cancer stem cell marker or
not.
In this study, we used monoclonal antibody against
the CD133/1 or AC133, one of the two epitopes of the
CD133 protein. The other epitope is AC141. Although, the
monoclonal antibodies against these two epitopes have
been interchangeably used to purify and characterize vari-
ous stem and progenitor cells [40] there is rarely discord-
ant expression of the AC133 and AC141 epitopes observed
such as in a study on patients with myelodysplastic syn-
drome and acute myelogenous leukemia [41]. In addition,
few important factors need to be considered while using
monoclonal antibodies against an epitope of CD133. First
of all, there is little known about the characteristics of the
two epitopes detected by the monoclonal antibodies. Sec-
ondly, these epitopes are suggested to be glycosylated
(however the supporting evidence for this claim is not well
verified in the existing literature [42]) and this glycosylation
is reported to be down-regulated upon differentiation of
epithelial cells. An additional confusing factor is the pres-
ence of alternatively spliced variants of CD133. There in
human CD133 gene exist at least 37 exons and several al-
ternatively spliced forms [21]. Although, there is little
knowledge about the existence of alternatively spliced
CD133 isoforms that lack the AC133 or AC141 epitopes,
the epitope-negative cells (cells that are negative against
the monoclonal antibodies such as the CD133 negative
cases in our study) may not solely and necessarily mean
CD133 negativity in the absence of proper verification of
CD133 protein or mRNA levels [42].
Additionally, it was recently concluded that AC133
does not recognize a glycosylated epitope, in contrast to
previous suggestions [43,44] and described that differen-
tial splicing is also not the cause of differential AC133
recognition. However, it remains for the future studies
to comparatively use antibodies against all known
glycosylated and non-glycosylated epitopes of CD133 to
draw a confident conclusion over the validity of the
tested monoclonal antibodies.
To validate our IHC results in CRCs, we also evaluated
CD133 mRNA expression in 75 cases out of 271 cases
which had available fresh frozen tissue. There was a sig-
nificant correlation between mRNA expression and
CD133 IHC expression (p=0.0257). Since the CD133
IHC expression happen to be observed only in tumor
(with the exception of rare cells in crypt base) and there
is significant direct correlation between the IHC and
mRNA expression level, there may be minute chance of
missing isoforms of CD133 (if any) that may lack
epitope-immunoreactivity via our IHC staining. Unfortu-
nately, we could not evaluate the prognostic significance
of CD133 mRNA expression according to the adjuvanttherapy status due to limitation in number of cases with
available fresh frozen tissue.
To verify the regulatory mechanism of CD133 ex-
pression, we performed methylation analysis and found
inverse correlation between CD133 expression and
promoter methylation level (p<0.0001). This finding is
concordant with previous study on colon cancer cell
lines [31]. But, the correlation of CD133 mRNA with
methylation was not statistically significant. The lack
of statistical significance in correlation between the
level of CD133 mRNA and promoter methylation sug-
gests that other factors may be additionally involved in
the regulation of CD133 expression.
We studied the correlation between CD133 IHC ex-
pression and patients’ survival in stage II and III CRCs.
Although CD133 IHC expression was not correlated
with OS (p=0.9778) and DFS (p=0.2451), the group of
patients with CD133+ CRC showed better OS if patients
received adjuvant therapy compared to patients without
adjuvant therapy in the Log-Rank test. Multivariate ana-
lysis adjusted with age and stage also showed statistical
significance between two groups (p<0.0001, HR 0.125,
95% CI 0.052-0.299). However the patients with CD133-
tumors did not show any difference in OS between two
groups (p=0.055, HR 0.500, 95% CI 0.247-1.015). There-
fore the adjuvant therapy can be of benefit for patients
with CD133+ tumor in contrast to patients with CD133-
one. This stands against the notion that tumors with
high CD133 positivity are resistant to adjuvant therapy
[39]. Our results are in support of a recent paper which
has demonstrated that CD133+ tumor cells are not more
resistant to chemotherapy than CD133- tumor cells [28].
Noteworthily, this finding asks for further elucidation of
the matter and moreover notifies that stage II and III
colon cancer patients with CD133 IHC expression may
benefit from adjuvant therapy. However, adjuvant ther-
apy status seemed not to have affected DFS in patients
with CD133+ as well as CD133- tumors. Our finding on
the one hand questions the non-response to chemother-
apy theory and on the other hand asks for further eluci-
dation of the precise prognostic role of CD133 as an
important prognostic factor for considering adjuvant
therapy in stage II and III colon cancer. Future cohort
studies with more number of patients in the two groups
according to adjuvant therapy may further enlighten this
finding.
Conclusion
In conclusion, CD133 expression in CRCs may be regu-
lated by promoter methylation and CD133 IHC expres-
sion notifies a better prognosis in stage II and III CRC
patients who have adjuvant therapy. However CD133
IHC expression is not an independent prognostic factor
in patients with stage II and III CRC.
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